Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer

por Telang, Nitin T., Nair, Hareesh B., Wong, George Y. C.
Publicado 2021

BU-32: a novel proteasome inhibitor for breast cancer

por Agyin, Joseph K, Santhamma, Bindu, Nair, Hareesh B, Roy, Sudipa S, Tekmal, Rajeshwar R
Publicado 2009

Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo

por Nair, Hareesh B., Santhamma, Bindu, Krishnegowda, Naveen K., Dileep, Kalarikkal V., Nickisch, Klaus J.
Publicado 2016

Targeting LIF/LIFR signaling in cancer

por Viswanadhapalli, Suryavathi, Dileep, Kalarickal V., Zhang, Kam Y.J., Nair, Hareesh B., Vadlamudi, Ratna K.
Publicado 2021

An efficient model of human endometriosis by induced unopposed estrogenicity in baboons

por Nair, Hareesh B., Baker, Robert, Owston, Michael A., Escalona, Renee, Dick, Edward J., VandeBerg, John L., Nickisch, Klaus J.
Publicado 2016

EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model

por Nair, Hareesh B., Santhamma, Bindu, Dileep, Kalarickal V., Binkley, Peter, Acosta, Kirk, Zhang, Kam Y. J., Schenken, Robert, Nickisch, Klaus
Publicado 2019

Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma

por Hall, Bradley R., Cannon, Andrew, Thompson, Christopher, Santhamma, Bindu, Chavez-Riveros, Alejandra, Bhatia, Rakesh, Nair, Hareesh B., Nickisch, Klaus, Batra, Surinder K., Kumar, Sushil
Publicado 2019

Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling

por Pradeep, Chaluvally-Raghavan, Köstler, Wolfgang J., Lauriola, Mattia, Granit, Roy, Zhang, Fan, Jacob-Hirsch, Jasmine, Rechavi, Gideon, Nair, Hareesh B., Hennessy, Bryan T., Gonzalez-Angulo, Ana M., Tekmal, Rajeshwar R., Ben-Porath, Ittai, Mills, Gordon, Domany, Eytan, Yarden, Yosef
Publicado 2011

Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth

por Blankenship, Logan, Pratap, Uday P., Yang, Xue, Liu, Zexuan, Altwegg, Kristin A., Santhamma, Bindu, Ramasamy, Kumaraguruparan, Konda, Swapna, Chen, Yidong, Lai, Zhao, Zheng, Siyuan, Sareddy, Gangadhara R., Valente, Philip T., Kost, Edward R., Nair, Hareesh B., Tekmal, Rajeshwar R., Vadlamudi, Ratna K., Viswanadhapalli, Suryavathi
Publicado 2022

Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling

por Singhal, Hari, Greene, Marianne E., Zarnke, Allison L., Laine, Muriel, Al Abosy, Rose, Chang, Ya-Fang, Dembo, Anna G., Schoenfelt, Kelly, Vadhi, Raga, Qiu, Xintao, Rao, Prakash, Santhamma, Bindu, Nair, Hareesh B., Nickisch, Klaus J., Long, Henry W., Becker, Lev, Brown, Myles, Greene, Geoffrey L.
Publicado 2017

LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer

por Tang, Weiwei, Ramasamy, Kumaraguruparan, Pillai, Sureshkumar M. A., Santhamma, Bindu, Konda, Swapna, Pitta Venkata, Prabhakar, Blankenship, Logan, Liu, Junhao, Liu, Zexuan, Altwegg, Kristin A., Ebrahimi, Behnam, Pratap, Uday P., Li, Xiaonan, Valente, Philip T., Kost, Edward, Sareddy, Gangadhara R., Vadlamudi, Ratna K., Nair, Hareesh B., Tekmal, Rajeshwar R., Viswanadhapalli, Suryavathi
Publicado 2021

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

por Li, Mengxing, Viswanadhapalli, Suryavathi, Santhamma, Bindu, Pratap, Uday P., Luo, Yiliao, Liu, Junhao, Altwegg, Kristin A., Tang, Weiwei, Liu, Zexuan, Li, Xiaonan, Ebrahimi, Behnam, Yan, Hui, Zou, Yi, Konda, Swapna, Sareddy, Gangadhara R., Xu, Zhenming, Chen, Yidong, Rao, Manjeet K., Brenner, Andrew J., Kaklamani, Virginia G., Tekmal, Rajeshwar R., Ahmed, Gulzar, Raj, Ganesh V., Nickisch, Klaus J., Nair, Hareesh B., Vadlamudi, Ratna K.
Publicado 2021